paroxetine has been researched along with glutamic acid in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (9.09) | 18.7374 |
| 1990's | 1 (9.09) | 18.2507 |
| 2000's | 3 (27.27) | 29.6817 |
| 2010's | 6 (54.55) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Cross, AJ; Reynolds, GP; Slater, P | 1 |
| MacMaster, FP; Moore, GJ; Rosenberg, DR; Stewart, C | 1 |
| Fitzgerald, KD; Keshavan, MS; MacMaster, FP; Moore, GJ; Rosenberg, DR; Stewart, CM | 1 |
| Bolton, J; MacMillan, S; Moore, GJ; Rosenberg, DR; Stewart, CM | 1 |
| Langman, NJ; Smith, CG; Whitehead, KJ | 1 |
| Fujimori, K; Sato, K; Sekino, Y; Shigemoto-Mogami, Y; Suzuki, T; Takaki, J | 1 |
| Conti, AC; Eagle, AL; Galloway, MP; George, SA; Gerard, J; Ghoddoussi, F; Harutyunyan, A; Hool, SM; Kohler, RJ; Liberzon, I; Mulo, K; Perrine, SA; Schneider, BL; Susick, LL | 1 |
| Asara, JM; Dournes, C; Filiou, MD; Ising, M; Müller, MB; Park, DI; Sillaber, I; Turck, CW; Webhofer, C | 1 |
| Bermudez, I; Csanova, A; Franklin, M; Hlavacova, N; Jezova, D; Li, Y; Sanchez, C | 1 |
| Bermudez, I; Csanova, A; Franklin, M; Hlavacova, N; Jezova, D; Li, Y; Pehrson, A; Sanchez, C | 1 |
11 other study(ies) available for paroxetine and glutamic acid
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Reduced high-affinity glutamate uptake sites in the brains of patients with Huntington's disease.
Topics: Aged; Aspartic Acid; Brain; Caudate Nucleus; Female; Frontal Lobe; Glutamates; Glutamic Acid; Hippocampus; Humans; Huntington Disease; Male; Middle Aged; Paroxetine; Piperidines; Putamen | 1986 |
Case study: caudate glutamatergic changes with paroxetine therapy for pediatric obsessive-compulsive disorder.
Topics: Caudate Nucleus; Child; Glutamic Acid; Humans; Magnetic Resonance Spectroscopy; Male; Models, Neurological; Obsessive-Compulsive Disorder; Paroxetine; Selective Serotonin Reuptake Inhibitors | 1998 |
Decrease in caudate glutamatergic concentrations in pediatric obsessive-compulsive disorder patients taking paroxetine.
Topics: Adolescent; Case-Control Studies; Caudate Nucleus; Child; Confounding Factors, Epidemiologic; Female; Glutamic Acid; Humans; Magnetic Resonance Spectroscopy; Male; Obsessive-Compulsive Disorder; Occipital Lobe; Paroxetine; Selective Serotonin Reuptake Inhibitors; Serotonin; Treatment Outcome | 2000 |
Case study: caudate glutamatergic changes with paroxetine persist after medication discontinuation in pediatric OCD.
Topics: Brain Chemistry; Caudate Nucleus; Child; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Glutamic Acid; Humans; Magnetic Resonance Spectroscopy; Obsessive-Compulsive Disorder; Paroxetine; Remission Induction; Selective Serotonin Reuptake Inhibitors | 2001 |
Selective serotonin re-uptake inhibition attenuates evoked glutamate release in the dorsal horn of the anaesthetised rat in vivo.
Topics: Anesthesia; Animals; Aspartic Acid; Citalopram; Glutamic Acid; Male; Microdialysis; Paroxetine; Piperazines; Posterior Horn Cells; Pyridines; Rats; Rats, Wistar; Receptor, Serotonin, 5-HT1A; Selective Serotonin Reuptake Inhibitors; Serotonin Antagonists | 2006 |
Paroxetine prevented the down-regulation of astrocytic L-Glu transporters in neuroinflammation.
Topics: Amino Acid Transport System X-AG; Antidepressive Agents; Astrocytes; Cells, Cultured; Down-Regulation; Glutamic Acid; Humans; Inflammation; Lipopolysaccharides; Microglia; Neurons; Paroxetine | 2015 |
Severe, multimodal stress exposure induces PTSD-like characteristics in a mouse model of single prolonged stress.
Topics: Animals; Behavior, Animal; Conditioning, Classical; Corticosterone; Cues; Disease Models, Animal; Extinction, Psychological; Fear; Glutamic Acid; Hippocampus; Male; Mice; Mice, Inbred C57BL; Paroxetine; Prefrontal Cortex; Receptors, Glucocorticoid; Restraint, Physical; Selective Serotonin Reuptake Inhibitors; Stress Disorders, Post-Traumatic; Stress, Psychological; Swimming | 2016 |
Delineation of molecular pathway activities of the chronic antidepressant treatment response suggests important roles for glutamatergic and ubiquitin-proteasome systems.
Topics: Animals; Antidepressive Agents; Depressive Disorder, Major; Glutamic Acid; Hippocampus; Humans; Leukocytes, Mononuclear; Male; Metabolomics; Mice; Mice, Inbred DBA; Nitric Oxide Synthase Type I; Paroxetine; Proteasome Endopeptidase Complex; Proteomics; Receptors, N-Methyl-D-Aspartate; Swimming; Ubiquitin | 2017 |
Contrasting effects of vortioxetine and paroxetine on pineal gland biochemistry in a tryptophan-depletion model of depression in female rats.
Topics: Administration, Oral; Animals; Antidepressive Agents, Second-Generation; Depressive Disorder; Disease Models, Animal; Female; Glutamic Acid; Melatonin; Norepinephrine; Paroxetine; Pineal Gland; Piperazines; Random Allocation; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate; RNA-Binding Proteins; Selective Serotonin Reuptake Inhibitors; Serotonin; Sulfides; Tryptophan; Vortioxetine | 2017 |
Effects of vortioxetine on biomarkers associated with glutamatergic activity in an SSRI insensitive model of depression in female rats.
Topics: Administration, Oral; Animals; Biomarkers; Depressive Disorder; Disease Models, Animal; Female; Glutamic Acid; Paroxetine; Random Allocation; Rats, Sprague-Dawley; Selective Serotonin Reuptake Inhibitors; Vortioxetine | 2018 |